Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning.

Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning.

Publication date: Sep 22, 2023

As the COVID-19 pandemic has evolved during the past years, interactions between human immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective vaccines have complicated the landscape of individual immunological histories. Here, we review some key findings for antibody and B cell-mediated immunity, including responses to the highly mutated omicron variants; immunological imprinting and other impacts of successive viral antigenic variant exposures on antibody and B cell memory; responses in secondary lymphoid and mucosal tissues and non-neutralizing antibody-mediated immunity; responses in populations vulnerable to severe disease such as those with cancer, immunodeficiencies, and other comorbidities, as well as populations showing apparent resistance to severe disease such as many African populations; and evidence of antibody involvement in postacute sequelae of infection or long COVID. Despite the initial phase of the pandemic ending, human populations will continue to face challenges presented by this unpredictable virus. Expected final online publication date for the Annual Review of Pathology: Mechanisms of Disease, Volume 19 is January 2024. Please see http://www. annualreviews. org/page/journal/pubdates for revised estimates.

Concepts Keywords
African Antibody
Annual Cov
Cancer Covid
Pandemic End
Vaccines Immunity


Type Source Name
disease IDO cell
disease MESH SARS-CoV-2 Infection
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccination
disease VO effective
disease MESH cancer
disease MESH sequelae
disease MESH infection
disease MESH long COVID
disease VO volume

Original Article

(Visited 1 times, 1 visits today)